<?xml version="1.0" encoding="UTF-8"?>
<p>According to the FDA, eligible recipients of convalescent plasma should be COVID-19 positive patients with severe disease (dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation 93% or less, partial pressure of arterial oxygen to fraction of inspired oxygen ratio less than 300, and/or lung infiltrates &gt; 50% within 24 to 48 hours) or a life-threatening disease (respiratory failure, septic shock, multiple organ dysfunction) who have given informed consent for the procedure.
 <sup>
  <xref rid="R40" ref-type="bibr">40</xref>
 </sup> Nevertheless, as evidenced by the registered trials (Tables 
 <xref rid="T2" ref-type="table">2</xref> and 
 <xref rid="T3" ref-type="table">3</xref>), a wide variety of selection criteria have been envisaged. Following the FDA's National Expanded Access Treatment Protocol, 2115 sites have registered to participate to convalescent plasma administration by April 27, 2020, enrolled a total of 5,968 patients, with 2576 receiving convalescent plasma.
 <sup>
  <xref rid="R43" ref-type="bibr">43</xref>
 </sup>
</p>
